Ott, Mary A. http://orcid.org/0000-0003-1347-2480
Crawley, Francis P. http://orcid.org/0000-0002-6893-5916
Sáez-Llorens, Xavier
Owusu-Agyei, Seth
Neubauer, David http://orcid.org/0000-0002-4564-5318
Dubin, Gary
Poplazarova, Tatjana http://orcid.org/0000-0002-1121-0236
Begg, Norman http://orcid.org/0000-0002-9441-1446
Rosenthal, Susan L.
Funding for this research was provided by:
GlaxoSmithKline (None - GSK covered meeting costs, editorial support)
Article History
First Online: 23 February 2018
Compliance with Ethical Standards
:
: Mary Ott’s spouse is an employee of Eli Lilly, Inc., and the couple are small stockholders in Eli Lilly, Inc. Gary Dubin is currently employed by Takeda Pharmaceuticals but was employed by the GSK group of companies for most of the period of manuscript development; he currently owns stocks in the GSK group of companies and was a co-inventor on a number of patents in the herpes simplex virus (HSV) and human papilloma virus (HPV) vaccine field. Tatjana Poplazarova is an employee of the GSK group of companies and holds shares in the GSK group of companies as part of her employee remuneration. Norman Begg was employed by the GSK group of companies at the time of manuscript development. He holds shares in, and acts as a consultant to, the GSK group of companies. Francis Crawley, Xavier Sáez-Llorens, Seth Owusu-Agyei, David Neubauer, and Susan Rosenthal have no conflicts of interest that are directly relevant to this article.